An international pharmaceutical company announced remarkably successful Phase III clinical trial results for a new, once-daily oral drug targeting chronic obesity, showcasing an average of 15% patient body weight loss over a year. The drug, which works similarly to existing injectable GLP-1 agonists, is expected to seek fast-track regulatory approval, potentially revolutionizing the obesity treatment market.
credit : ดูหนัง2025